Sign in Subscribe

article

A collection of 632 issues

Trifluridine/tipiracil outcomes examined in patients 75 and older

Skip to content The CRC Digest ▸ TREATMENT Trifluridine/tipiracil outcomes examined in patients 75 and older A single-center retrospective study compared relative dose intensity, toxicity, and survival between trifluridine/tipiracil (FTD/TPI) monotherapy and FTD/TPI plus bevacizumab in older patients with metastatic colorectal cancer, examining the relationship between dose

Multitarget stool DNA test shows promise over standard FIT screening

Skip to content The CRC Digest ▪ SCREENING Multitarget stool DNA test shows promise over standard FIT screening A systematic review found that multitarget stool DNA (mt-sDNA) testing emerged as a promising alternative to faecal immunochemical test (FIT) for detecting colorectal neoplasms, particularly given FIT's low sensitivity for advanced

Younger CRC Patients Face Distinct Quality of Life Challenges

Skip to content The CRC Digest Younger CRC Patients Face Distinct Quality of Life Challenges A qualitative study comparing early-onset colorectal cancer patients to older patients found that young people with colorectal cancer experience worse psychological wellbeing, including marked emotional distress and prominent levels of anxiety. (Quality of Life Research)

Rare DPYD Variant Linked to Severe Fluoropyrimidine Toxicity

Skip to content The CRC Digest ▸ TREATMENT Rare DPYD Variant Linked to Severe Fluoropyrimidine Toxicity A 50-year-old colorectal cancer patient developed life-threatening grade 3-4 toxicities after adjuvant XELOX; sequencing identified a rare intronic DPYD variant (c.2766+3A>T) that causes exon 21 skipping and profound DPD deficiency, which

Anorectal Visits Offer Missed Screening Opportunity for Adults Under 50

Skip to content The CRC Digest ▪ SCREENING Anorectal Visits Offer Missed Screening Opportunity for Adults Under 50 Among 776 patients seen for benign anorectal conditions, only 60.5% of adults aged 45-49 had undergone colonoscopy in the prior 10 years, highlighting a missed opportunity to promote screening during routine visits.

Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC A matching-adjusted indirect comparison evaluated sotorasib plus panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice.

KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic

Serbian cohort reveals MLH1 as predominant Lynch syndrome variant

Skip to content The CRC Digest Serbian cohort reveals MLH1 as predominant Lynch syndrome variant Germline testing of 176 high-risk individuals in Serbia identified pathogenic variants predominantly in MLH1, highlighting the need for population-specific genetic testing strategies in hereditary colorectal cancer screening. (Int J Mol Sci) This content is informational

Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer

Skip to content The CRC Digest Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer Analysis of over 30,000 tumors found that co-mutation of CREBBP/EP300 and POLE/POLD1 strongly predicted elevated tumor mutational burden in microsatellite-stable disease (median 155.9 vs.

Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment The PROSPER trial will test lecithinized superoxide dismutase (PC-SOD) against placebo to prevent chemotherapy-induced peripheral neuropathy in stage II/III colorectal cancer patients receiving adjuvant mFOLFOX6, following promising phase II